Cipher Pharmaceuticals, Inc. (CPH) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cipher Pharmaceuticals, Inc.

Rubicon Organics, Inc.

Jamieson Wellness, Inc.

Decibel Cannabis Co., Inc.

Cronos Group, Inc.

Else Nutrition Holdings, Inc.

The Cannabist Company Holdings, Inc.

BioNxt Solutions, Inc.

Eastwood Bio-Medical Canada, Inc.

Grown Rogue International, Inc.

Filament Health Corp.

Why is Cipher Pharmaceuticals, Inc. ?

High Management Efficiency with a high ROE of 25.10%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.64

With a growth in Net Profit of 116.61%, the company declared Very Positive results in Jun 25

The company has declared positive results in Jan 70 after 2 consecutive negative quarters
OPERATING CASH FLOW(Y) Highest at CAD 29.43 MM
NET SALES(Q) Highest at CAD 18.52 MM
INVENTORY TURNOVER RATIO(HY) Highest at 4.72%

With ROE of 11.37%, it has a fair valuation with a 2.70 Price to Book Value

The stock is trading at a fair value compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 12.42%, its profits have fallen by -44.5%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Cipher Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Cipher Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Cipher Pharmaceuticals, Inc.

39.4%

1.57

50.96%

S&P/TSX 60

23.72%

1.54

14.62%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

19.49%

EBIT Growth (5y)

7.12%

EBIT to Interest (avg)

12.64

Debt to EBITDA (avg)

0.38

Net Debt to Equity (avg)

0.17

Sales to Capital Employed (avg)

0.29

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

37.30%

ROE (avg)

25.10%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.46

EV to EBIT

18.40

EV to EBITDA

12.78

EV to Capital Employed

2.49

EV to Sales

6.00

PEG Ratio

0.08

Dividend Yield

ROCE (Latest)

13.52%

ROE (Latest)

21.99%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 41.64 MM

NET SALES(HY)

At CAD 36.2 MM has Grown at 69.16%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

PRE-TAX PROFIT(Q)

At CAD 5.86 MM has Grown at 192.08%

RAW MATERIAL COST(Y)

Fallen by -8.56% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 4.38 times

OPERATING PROFIT MARGIN(Q)

Highest at 52.76 %

NET PROFIT(Q)

At CAD 7.58 MM has Grown at 78.38%

-8What is not working for the Company

INTEREST(HY)

At CAD 0.81 MM has Grown at 103.28%

Here's what is working for Cipher Pharmaceuticals, Inc.

Pre-Tax Profit

At CAD 5.86 MM has Grown at 192.08%

over average net sales of the previous four periods of CAD 2.01 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CAD MM)

Net Sales

At CAD 36.2 MM has Grown at 69.16%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Operating Cash Flow

Highest at CAD 41.64 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Operating Profit Margin

Highest at 52.76 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Net Profit

At CAD 7.58 MM has Grown at 78.38%

over average net sales of the previous four periods of CAD 4.25 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

Debtors Turnover Ratio

Highest at 4.38 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -8.56% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Cipher Pharmaceuticals, Inc.

Interest

At CAD 0.81 MM has Grown at 103.28%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)